The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VYGR | -26.78% | -50.12% | -12.99% | -77% |
| S&P | +15.98% | +86.41% | +13.26% | +231% |
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
These biotech companies are seeing a spike in revenue growth.
Investors are taking profits on this red-hot stock this week.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $13.37M | -45.7% |
| Gross Profit | $12.43M | -47.1% |
| Gross Margin | 93.03% | -2.4% |
| Market Cap | $259.04M | -18.8% |
| Market Cap / Employee | $1.51M | 0.0% |
| Employees | 172 | 6.2% |
| Net Income | -$27,892.00K | -208.4% |
| EBITDA | -$29,662.00K | -134.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $45.13M | -59.9% |
| Accounts Receivable | $3.19M | -80.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $30.52M | -20.5% |
| Short Term Debt | $7.85M | 12.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -35.50% | -42.7% |
| Return On Invested Capital | -12.06% | 2.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$31,255.00K | -10.7% |
| Operating Free Cash Flow | -$31,048.00K | -11.0% |
| Metric | Q4 2023 | Q2 2024 | Q3 2024 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 2.73 | 27.61 | 8.12 | - | |
| Price to Book | 0.94 | 0.62 | 0.63 | 1.06 | 11.71% |
| Price to Sales | 4.11 | 2.95 | 4.28 | 8.77 | 324.38% |
| Price to Tangible Book Value | 0.94 | 0.62 | 0.63 | 1.06 | 11.71% |
| Price to Free Cash Flow TTM | 5.10 | 64.59 | - | ||
| Enterprise Value to EBITDA | -2.84 | -0.09 | -0.20 | -3.51 | 15.49% |
| Free Cash Flow Yield | 19.6% | 1.5% | - | ||
| Return on Equity | -24.3% | -27.6% | -37.3% | -46.1% | -551.05% |
| Total Debt | $43.73M | $42.00M | $40.20M | $38.37M | -15.39% |
No podcast episodes available.
VYGR earnings call for the period ending December 31, 2019.
VYGR earnings call for the period ending September 30, 2019.
VYGR earnings call for the period ending June 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
